You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Foundation Medicine will provide genomic profiling for the EORTC's Screening Patients for Efficient Clinical Trial Access program.
At the JPM Healthcare Conference on Wednesday, its CEO also said that lower-than-anticipated revenues in Q4 2017 were due to a longer-than-expected sales cycle.
At the San Antonio Breast Cancer Symposium, Myriad reported on the ability of its 86 SNP score to predict disease risk for the majority of women of European ancestry.
The $12 million PRIME study will involve 2,000 veterans with major depressive disorder and 250 healthcare providers across 21 VA medical centers.
BioSequence is looking to raise the profile of its genomic offering among clinicians, and to strengthen its case for reimbursement.
Next year, the company will submit regulatory filings for the drug in two molecularly defined indications and a next-generation sequencing companion diagnostic.
The study, launched today, aims to evaluate the use of liquid biopsy and natural killer cell testing for the early detection of recurrent breast cancer.
The company expects the new trials to start this fall, and plans to submit to the FDA next year to get the agency's stamp of approval.
The firm said that prior to entering clinical trials, it also needs to reduce failure rates of a cassette that is part of the Verigene 2 test.
The trial aims to validate a biomarker panel that includes Volition's colorectal cancer test in a large asymptomatic population in support of US regulatory approval.